Cargando…

MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines

BACKGROUND:The MAP2K1 K57T mutation is known to be a potential mechanism of primary and secondary resistance to EGFR inhibitors in metastatic colorectal cancer (CRC) and has also been reported to promote resistance to BRAF and MEK inhibitors. It is important to overcome therapeutic resistance to EGF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, J. E., Kim, K.K., Kim, S. Y., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., Kim, S. T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560144/ https://www.ncbi.nlm.nih.gov/pubmed/28819429 http://dx.doi.org/10.7150/jca.19582

Ejemplares similares

Differential regulation of MAP kinase cascade in human colorectal tumorigenesis
por: Park, K-S, et al.
Publicado: (1999)

A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer
por: Lim, S H, et al.
Publicado: (2015)

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
por: Lee, D-W, et al.
Publicado: (2013)

The beneficial effect of palliative resection in metastatic colorectal cancer
por: Park, J H, et al.
Publicado: (2013)

The relationship between microvessel count and the expression of vascular endothelial growth factor, p53, and K-ras in non-small cell lung cancer.
por: Kang, Y. H., et al.
Publicado: (2001)

Association of serum lipids and glucose with the risk of colorectal adenomatous polyp in men: a case-control study in Korea.
por: Park, S. K., et al.
Publicado: (2000)

Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma
por: Lee, S, et al.
Publicado: (2010)

Increased serum levels of mutant p53 proteins in patients with colorectal cancer.
por: Shim, K. S., et al.
Publicado: (1998)

Germline mutations of the STK11 gene in Korean Peutz–Jeghers syndrome patients
por: Yoon, K-A, et al.
Publicado: (2000)

Establishment and characterisation of six human biliary tract cancer cell lines
por: Ku, J-L, et al.
Publicado: (2002)

Nurses' assessment of postoperative pain: can it be an alternative to patients' self-reports?
por: Chung, I. S., et al.
Publicado: (2001)

Expression of MAGE-1, -2, and -3 genes in gastric carcinomas and cancer cell lines derived from Korean patients.
por: Kim, Y. M., et al.
Publicado: (2001)

von Willebrand disease with G4022A mutation (vWd Sungnam): a case report.
por: Song, K. S., et al.
Publicado: (1999)

Role of tissue inhibitors of metalloproteinases (TIMPs) in colorectal carcinoma.
por: Joo, Y. E., et al.
Publicado: (1999)

S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
por: Kim, S Y, et al.
Publicado: (2013)

NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines
por: Kim, Sun Young, et al.
Publicado: (2018)

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
por: Lee, J-L, et al.
Publicado: (2008)

Topographic expression of p21WAF1/SDI1/CIP1, bcl2, and p53 is altered at the early stage of colorectal carcinogenesis.
por: Cho, J. H., et al.
Publicado: (2000)

Colorectal adenocarcinoma as a second malignant neoplasm following rhabdomyosarcoma of the urinary bladder: a case report.
por: Park, S. S., et al.
Publicado: (2000)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
por: Kim, S T, et al.
Publicado: (2018)

Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
por: Park, H.S., et al.
Publicado: (2021)

BRAF mutations in non-Hodgkin's lymphoma
por: Lee, J W, et al.
Publicado: (2003)

Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
por: Lee, J. H., et al.
Publicado: (2001)

Hereditary protein C deficiency with recurrent thrombosis: identification of a missense mutation (C6218T).
por: Song, K. S., et al.
Publicado: (1998)

Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon.
por: Lee, J. T., et al.
Publicado: (1996)

Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer
por: Kim, Jinchul, et al.
Publicado: (2021)

A monoclonal antibody to common acute lymphoblastic leukemia antigen (CALLA) and its expression on several human tumor cell lines.
por: Park, W. S., et al.
Publicado: (1992)

Risk of transmission of COVID-19 from healthcare workers returning to work after a 5-day isolation, and kinetics of shedding of viable SARS-CoV-2 variant B.1.1.529 (Omicron)
por: Jung, J., et al.
Publicado: (2023)

A macrophage-specific synthetic promoter for therapeutic application of adiponectin
por: Kang, W S, et al.
Publicado: (2014)

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer
por: Kim, S T, et al.
Publicado: (2005)

A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer
por: Park, Y H, et al.
Publicado: (2006)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix
por: Park, J-Y, et al.
Publicado: (2010)

Interferon consensus sequence-binding protein (ICSBP) promotes epithelial-to-mesenchymal transition (EMT)-like phenomena, cell-motility, and invasion via TGF-β signaling in U2OS cells
por: Sung, J Y, et al.
Publicado: (2014)

Effect of suramin on differentiation of human stomach cancer cell lines.
por: Choe, G., et al.
Publicado: (1997)

Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR
por: Lim, Yoojoo, et al.
Publicado: (2021)

Experience of orthotopic liver transplantation in 11 patients with liver cirrhosis from Korea: medical factors affecting outcome.
por: Choi, J. Y., et al.
Publicado: (1998)

Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view
por: Lim, D H, et al.
Publicado: (2004)

Optimal anticoagulation intensity with warfarin for the prevention of thromboembolism with minimal bleeding in Asian patients with atrial fibrillation: multi-center, randomized controlled trial
por: Lee, K H, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mn2t8vboqp8gll3p3mrsuo0q40